Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT07508254

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Punjab Institute of Cardology (from the registry)
Registry
  • NCT NCT07508254
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07508254. Randomized; no masking; primary purpose treatment. Start 2026-05-01 (anticipated); primary completion 2026-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
Acronym
TLD-ACS
Condition
Acute Coronary Syndromes (ACS)
Condition
Hypercholesterolemia
Intervention (Drug)
Atorvastatin 40 Mg Oral Tablet
Intervention (Drug)
Ezetimibe 10 mg
Intervention (Drug)
Bempedoic Acid 180 MG Oral Tablet
Lead sponsor
Punjab Institute of Cardology (class: other)

Record details

Record id
cardio:ct-nct07508254
Content hash
bf4f954a3b12a59635d406231dbfd00ff6a0fe36fda4f980a33218781c422036